Evidence map›Paper›PMID 24743186›Full record

ArticlePloS one2014

Involvement of ANXA5 and ILKAP in susceptibility to malignant melanoma.

Yoana Arroyo-Berdugo, Santos Alonso, Gloría Ribas, Maider Ibarrola-Villava, María Peña-Chilet, Conrado Martínez-Cadenas, Jesús Gardeazabal, Juan Antonio Ratón-Nieto, Ana Sánchez-Díez, Jesús María Careaga and 7 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.9field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Annexin Animal Models-From Fundamental Principles to Translational Research.International journal of molecular sciences · 2021
    Review
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 8 institutions in 1 country.

Yoana Arroyo-BerdugoDepartment of Cell Biology and Histology, School of Medicine and Dentistry, University of the Basque Country (UPV/EHU), Leioa, Bizkaia, Spain.
Santos AlonsoDepartment of Genetics, Physical Anthropology and Animal Physiology, Faculty of Science and Technology, University of the Basque Country (UPV/EHU), Leioa, Bizkaia, Spain.
Gloría RibasDepartment of Hematology and Medical Oncology, Instituto Investigación Sanitaria, INCLIVA, Valencia, Spain.
Maider Ibarrola-VillavaDepartment of Hematology and Medical Oncology, Instituto Investigación Sanitaria, INCLIVA, Valencia, Spain.
María Peña-ChiletDepartment of Hematology and Medical Oncology, Instituto Investigación Sanitaria, INCLIVA, Valencia, Spain.
Conrado Martínez-CadenasDepartment of Medicine, University of Castellon Jaume I, Castellon, Spain.
Jesús GardeazabalDepartment of Dermatology, Ophthalmology and Otorhinolaryngology, UPV/EHU, Service of Dermatology, BioCruces Health Research Institute, Cruces University Hospital, Barakaldo, Bizkaia, Spain.
Juan Antonio Ratón-NietoDepartment of Dermatology, Ophthalmology and Otorhinolaryngology, UPV/EHU, Service of Dermatology, BioCruces Health Research Institute, Cruces University Hospital, Barakaldo, Bizkaia, Spain.
Ana Sánchez-DíezDepartment of Dermatology, Ophthalmology and Otorhinolaryngology, UPV/EHU, Service of Dermatology, BioCruces Health Research Institute, Basurto University Hospital, Bilbao, Bizkaia, Spain.
Jesús María CareagaDepartment of Dermatology, Ophthalmology and Otorhinolaryngology, UPV/EHU, Service of Dermatology, BioCruces Health Research Institute, Basurto University Hospital, Bilbao, Bizkaia, Spain.
Gorka Pérez-YarzaDepartment of Cell Biology and Histology, School of Medicine and Dentistry, University of the Basque Country (UPV/EHU), Leioa, Bizkaia, Spain.
Gregorio CarreteroDepartment of Dermatology, Doctor Negrin Hospital, Las Palmas de Gran Canaria, Spain.
Manuel Martín-GonzálezDepartment of Dermatology, Ramón y Cajal Hospital, Madrid, Spain.
Cristina Gómez-FernándezDeparment of Dermatology, La Paz University Hospital, Madrid, Spain.
Eduardo NagoreDepartment of Dermatology, Instituto Valenciano de Oncología, Valencia, Spain.
Aintzane AsumendiDepartment of Cell Biology and Histology, School of Medicine and Dentistry, University of the Basque Country (UPV/EHU), Leioa, Bizkaia, Spain.
María Dolores BoyanoDepartment of Cell Biology and Histology, School of Medicine and Dentistry, University of the Basque Country (UPV/EHU), Leioa, Bizkaia, Spain.
University of the Basque Country · ESINCLIVA Health Research Institute · ESBioCruces Health research Institute · ESHospital de Cruces · ESFundación Instituto Valenciano de Oncología · ESHospital Universitario de Gran Canaria Doctor Negrín · ESHospital Universitario La Paz · ESUniversitat Jaume I · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Single nucleotide-polymorphisms (SNPs) are a source of diversity among human population, which may be responsible for the different individual susceptibility to diseases and/or response to drugs, among other phenotypic traits. Several low penetrance susceptibility genes associated with malignant melanoma (MM) have been described, including genes related to pigmentation, DNA damage repair and oxidative stress pathways. In the present work, we conducted a candidate gene association study based on proteins and genes whose expression we had detected altered in melanoma cell lines as compared to normal melanocytes. The result was the selection of 88 loci and 384 SNPs, of which 314 fulfilled our quality criteria for a case-control association study. The SNP rs6854854 in ANXA5 was statistically significant after conservative Bonferroni correction when 464 melanoma patients and 400 controls were analyzed in a discovery Phase I. However, this finding could not be replicated in the validation phase, perhaps because the minor allele frequency of SNP rs6854854 varies depending on the geographical region considered. Additionally, a second SNP (rs6431588) located on ILKAP was found to be associated with melanoma after considering a combined set of 1,883 MM cases and 1,358 disease-free controls. The OR was 1.29 (95% CI 1.12-1.48; p-value = 4×10-4). Both SNPs, rs6854854 in ANXA5 and rs6431588 in ILKAP, show population structure, which, assuming that the Spanish population is not significantly structured, suggests a role of these loci on a specific genetic adaptation to different environmental conditions. Furthermore, the biological relevance of these genes in MM is supported by in vitro experiments, which show a decrease in the transcription levels of ANXA5 and ILKAP in melanoma cells compared to normal melanocytes.

Indexed as

Annexin A5Case-Control StudiesCell Line, TumorGene FrequencyGenetic Predisposition to DiseaseGenotypeHumansMelanomaPhosphoprotein PhosphatasesPolymorphism, Single NucleotideAnnexin A5ILKAP protein, humanPhosphoprotein Phosphatases

Identifiers

PMID24743186
PMCPMC3990692
OpenAlexW2048288183

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.